-
公开(公告)号：WO2020176797A1
公开(公告)日：2020-09-03
申请号：PCT/US2020/020224
申请日：2020-02-27
Applicant: NEKTAR THERAPEUTICS , VACCIBODY AS
Inventor： ZALEVSKY, Jonathan , FREDRIKSEN, Agnete Brunsvik , AXELSEN, Mads , SCHJETNE, Karoline
Abstract: Provided herein are methods, combinations, and compositions for treating a subject having cancer by administering to the subject an individualized neoantigen DNA cancer vaccine in combination with a T cell expanding compound ("T cell expander"), i.e., a compound capable of driving specific clonal T cell expansion to vaccine epitopes, optionally further combined with a checkpoint inhibitor.
-
公开(公告)号：WO2017118702A1
公开(公告)日：2017-07-13
申请号：PCT/EP2017/050216
申请日：2017-01-05
Applicant: VACCIBODY AS
Inventor： FREDRIKSEN, Agnete Brunsvik
CPC classification number: A61K39/0011 , A61K2039/53
Abstract: The present invention relates to an anticancer vaccine comprising polynucleotides or polypeptides, methods of treatment of cancer wherein such an anticancer vaccine is used as well as methods for producing the vaccine. The vaccine comprises a polynucleotide comprising a nucleotide sequence encoding a targeting unit, a dimerization unit, a first linker and an antigenic unit, wherein said antigenic unit comprises n-1 antigenic subunits, each subunit comprising at least a part of a cancer neoepitope sequence and a second linker and said antigenic unit further comprising a final cancer neoepitope sequence, wherein n is an integer of from 3 to 50, or the vaccine comprises a polypeptide encoded by the polynucleotide or a dimeric protein consisting of two polypeptides encoded by the polynucleotide.
Abstract translation: 本发明涉及包含多核苷酸或多肽的抗癌疫苗，其中使用了所述抗癌疫苗的癌症治疗方法以及生产所述疫苗的方法。 疫苗包含含有编码靶向单元，二聚化单元，第一接头和抗原单元的核苷酸序列的多核苷酸，其中所述抗原单元包含n-1个抗原亚基，每个亚基包含至少一部分癌新表位序列和 第二接头并且所述抗原单元还包含最终的癌新表位序列，其中n是3-50的整数，或者所述疫苗包含由所述多核苷酸编码的多肽或由所述多核苷酸编码的两个多肽组成的二聚体蛋白。 / p>
-
公开(公告)号：WO2021205027A1
公开(公告)日：2021-10-14
申请号：PCT/EP2021/059353
申请日：2021-04-09
Applicant: VACCIBODY AS
Inventor： FREDRIKSEN, Agnete, Brunsvik , SEKELJA, Monika , SCHJETNE, Karoline , GRANUM, Stine
Abstract: The present invention relates to an individualized therapeutic anticancer vaccine, methods of treatment of cancer wherein such an anticancer vaccine is used as well as methods for producing the vaccine.
-
公开(公告)号：WO2017221072A3
公开(公告)日：2017-12-28
申请号：PCT/IB2017/000946
申请日：2017-06-21
Applicant: UNIVERSITY OF OSLO , VACCIBODY AS
Inventor： GRODELAND, Gunnveig , BOGEN, Bjarne , FREDRIKSEN, Agnete, B.
Abstract: The present invention relates to an immunoglobulin derived single-chain fragment variable (scFv) that broadly binds HLA II molecules and uses thereof. In particular, targeting of an antigen to antigen presenting cells with the HLAII-specific targeting unit provided herein find use in enhancing immune responses after vaccination.
-
公开(公告)号：WO2021219897A1
公开(公告)日：2021-11-04
申请号：PCT/EP2021/061602
申请日：2021-05-03
Applicant: VACCIBODY AS
Inventor： FREDRIKSEN, Agnete, Brunsvik , SEKELJA, Monika , SCHJETNE, Karoline , NORHEIM, Gunnstein , STUBSRUD, Elisabeth
IPC: C07K14/165 , A61K39/12 , A61P31/14 , A61K39/00
Abstract: Disclosed is a vaccine comprising an immunologically effective amount of a polynucleotide comprising a nucleotide sequence encoding a targeting unit, a dimerization unit and an antigenic unit, wherein the antigenic unit comprises at least one betacoronavirus epitope. The vaccine is ideal for pandemic and epidemics as it can induce rapid, strong immune response with lower/fewer doses because the antigen is targeted to antigen presenting cells and the antigen is produced in the body.
-
Patent Agency Ranking
公开(公告)号：WO2020065023A1
公开(公告)日：2020-04-02
申请号：PCT/EP2019/076210
申请日：2019-09-27
Applicant: VACCIBODY AS
Inventor： SEKELJA, Monika , SCHJETNE, Karoline , FREDRIKSEN, Agnete, Brunsvik
Abstract: The present invention relates to a method for selecting neoepitopes for an individual, by selecting MHC I and/or MHC II binding neoepitopes and ranking them with respect the methods as described herein.
-
公开(公告)号：WO2011161244A1
公开(公告)日：2011-12-29
申请号：PCT/EP2011/060628
申请日：2011-06-24
Applicant: VACCIBODY AS , RUFFINI, Pier Adelchi , BOGEN, Bjarne , FREDRIKSEN, Agnete Brunsvik
Inventor： RUFFINI, Pier Adelchi , BOGEN, Bjarne , FREDRIKSEN, Agnete Brunsvik
CPC classification number: C07K16/28 , A61K39/0011 , A61K39/12 , A61K39/145 , A61K2039/53 , A61K2039/54 , A61K2039/6031 , A61K2039/6056 , C07K16/44 , C07K2317/526 , C07K2317/53 , C07K2317/622 , C07K2317/64 , C07K2319/30 , C07K2319/33 , C07K2319/40 , C07K2319/42 , C12N2760/16111 , C12N2760/16134
Abstract: The present disclosure relates to recombinant fusion proteins, such as human antibody- based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present disclosure also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins.
Abstract translation: 本公开涉及重组融合蛋白，例如称为Vaccibody的基于人抗体的分子，其能够触发T细胞和B细胞免疫应答。 本公开还涉及通过这些特异性融合蛋白治疗癌症或感染性疾病的方法。
-
公开(公告)号：WO2017221072A2
公开(公告)日：2017-12-28
申请号：PCT/IB2017/000946
申请日：2017-06-21
Applicant: UNIVERSITY OF OSLO , VACCIBODY AS
Inventor： GRODELAND, Gunnveig , BOGEN, Bjarne , FREDRIKSEN, Agnete, B.
IPC: A61K39/00
Abstract: The present invention relates to an immunoglobulin derived single-chain fragment variable (scFv) that broadly binds HLA II molecules and uses thereof. In particular, targeting of an antigen to antigen presenting cells with the HLAII-specific targeting unit provided herein find use in enhancing immune responses after vaccination.
Abstract translation: 本发明涉及广泛结合HLA II分子的免疫球蛋白衍生的单链片段变体（scFv）及其用途。 具体而言，用本文提供的HLAII特异性靶向单元将抗原靶向抗原呈递细胞可用于增强疫苗接种后的免疫应答。
-
公开(公告)号：WO2017118695A1
公开(公告)日：2017-07-13
申请号：PCT/EP2017/050206
申请日：2017-01-05
Applicant: VACCIBODY AS
Inventor： GRANUM, Stine , STUBSRUD, Elisabeth , FREDRIKSEN, Agnete Brunsvik
CPC classification number: A61K39/0011 , A61K2039/53 , A61K2039/6031 , A61K2039/6056 , A61K2039/627 , A61K2039/64 , A61K2039/70
Abstract: The present invention relates to an anticancer vaccine comprising polynucleotides or polypeptides, methods of treatment of cancer wherein such an anticancer vaccine is used as well as methods for producing the vaccine. The vaccine comprises a polynucleotide comprising a nucleotide sequenceencoding a targeting unit, a dimerization unit, a first linker and an antigenic unit, wherein said antigenic unit comprises n-1 antigenic subunits, each subunit comprising at least a part of a cancer neoepitope sequence and a second linker and said antigenic unit further comprising a final cancer neoepitope sequence, wherein n is an integer of from 3 to 50, or the vaccine comprises a polypeptide encoded by the polynucleotide or a dimeric protein consisting of two polypeptides encoded by the polynucleotide.
Abstract translation: 本发明涉及包含多核苷酸或多肽的抗癌疫苗，其中使用了所述抗癌疫苗的癌症治疗方法以及生产所述疫苗的方法。 疫苗包含含有编码靶向单元，二聚化单元，第一接头和抗原单元的核苷酸序列的多核苷酸，其中所述抗原单元包含n-1个抗原亚基，每个亚基包含至少一部分癌新表位序列和 第二接头和所述抗原单元进一步包含最终的癌新表位序列，其中n是3至50的整数，或者所述疫苗包含由所述多核苷酸编码的多肽或由所述多核苷酸编码的两个多肽组成的二聚体蛋白。 p>
-
公开(公告)号：WO2014140176A1
公开(公告)日：2014-09-18
申请号：PCT/EP2014/054961
申请日：2014-03-13
Applicant: VACCIBODY AS
IPC: C07K16/28 , A61K39/395
CPC classification number: C07K16/2833 , A61K39/3955 , C07K14/005 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/622 , C07K2317/64 , C07K2319/00 , C12N7/00 , C12N2710/16034 , C12N2710/16631
Abstract: The present invention relates to therapeutic compounds, such as vaccines against avian diseases and in particular to DNA vaccines. The invention further relates to protein construct encoding homodimeric peptides, which peptides may be released from a DNA vaccine or used separately. Further described are pharmaceutical formulations, host cells and methods for producing the vaccines, as well as methods for the treatment or prevention of various diseases in animals, such as avians, such as cancers and infectious diseases.
Abstract translation: 本发明涉及治疗性化合物，例如针对禽类疾病的疫苗，特别是DNA疫苗。 本发明还涉及编码同二聚体肽的蛋白质构建体，该肽可以从DNA疫苗中释放或分开使用。 进一步描述的是药物制剂，宿主细胞和用于生产疫苗的方法，以及用于治疗或预防动物诸如禽类如癌症和感染性疾病的各种疾病的方法。
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.014 seconds)
